Clinical Trial Update: Sorafenib in Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial of sorafenib in myelodysplastic syndromes and chronic myelomonocytic leukemia was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Duke University | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2014-02-11